News | Heart Failure | November 01, 2018

Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

Companies will conduct pilot study assessing benefits of using Daxor’s BVA-100 Blood Volume Analyzer with CHF Solutions’ Aquadex FlexFlow System

Daxor Corp. Collaborating With CHF Solutions on Heart Failure Fluid Overload Management

CHF Solutions' Aquadex FlexFlow System

November 1, 2018 — Daxor Corp. has entered an agreement with CHF Solutions to explore clinical synergies between Daxor’s BVA-100 Blood Volume Analyzer and CHF Solutions’ Aquadex FlexFlow System for heart failure patients. More specifically, the two companies will assess the benefit of combining Daxor’s fluid volume diagnostic with Aquadex FlexFlow therapy for the management of the fluid-overloaded patient.

The collaboration will initiate with an evaluation of the benefits of blood volume measurement in helping to determine ultrafiltration management with CHFS’s Aquadex FlexFlow system in a pilot study. Recently published outcomes of 245 heart failure admissions showed a decrease in heart failure mortality of 86 percent and 30-day readmissions of 56 percent when the BVA-100 diagnostic was used to guide treatment. A subset of those data included treatment using the Aquadex FlexFlow system to reduce fluid overload. The pilot study is intended to provide additional insight on the potential benefit of using the devices in tandem to enhance clinical outcomes. Specific points of inquiry will include how the two systems can assist with informing clinicians on fluid volume status including patient selection, when to start ultrafiltration therapy, and how to manage therapy to achieve positive clinical results for patients.

Read the article "Acute Heart Failure Mortality, Rehospitalizations Reduced With Blood Volume Measurement"

For more information: www.daxor.com, www.chf-solutions.com

Related Content

The U.S. Food and Drug Administration (FDA) has granted market clearance for AstraZeneca's dapagliflozin (Farxiga) to reduce the risk of hospitalization for heart failure (HF) in adults with type 2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
Feature | Heart Failure | October 21, 2019 | Dave Fornell, Editor
October 21, 2019 – The U.S.
Research Shows Drug Can Extend Survival Rates for Heart Failure Patients
News | Heart Failure | October 16, 2019
Researchers have shown for the first time in preclinical studies that the drug Aliskiren can delay the progression of...
The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms. #TMVR #TCT2019 #TCT19

The COAPT Economic Analysis sub-study found it is cost effective to treat heart failure patients who have severe secondary mitral regurgitation with MitraClip to reduce their MR symptoms.

News | Heart Failure | October 04, 2019
October 4, 2019 – Results of a new economic analysis of the COAPT Trial data found that transcatheter mitral valve re
COAPT Trial three-year data show the MitraClip continued effectiveness in heart failure patients with secondary mitral reguritation. #TCT2019 #TCT19 #mitralclip

COAPT Trial three-year data show the MitraClip continues to show safety and effectiveness in heart failure patients with secondary mitral reguritation.

News | Heart Failure | October 03, 2019
October 3, 2019 – The three-year results from the...
Positive Safety, Efficacy Data Reported on AccuCinch Heart Failure Device
News | Heart Failure | September 27, 2019
Ancora Heart Inc. announced results from an interim analysis of heart failure patients treated in the CorCinch FMR...
Max and Debra Ernst Heart Center Opening at Beaumont Hospital, Royal Oak
News | Heart Failure | September 20, 2019
The new Max and Debra Ernst Heart Center at Beaumont Hospital, Royal Oak, Mich., will open Sept. 30. It is dedicated to...
FDA Grants Fast Track Designation for Farxiga in Heart Failure
News | Heart Failure | September 18, 2019
AstraZeneca announced the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the...
Corvia Medical and physIQ Partner in Global Phase 3 Heart Failure Device Clinical Trial

The REDUCE LAP HF-II study will combine Corvia Medical's InterAtrial Shunt Device (IASD), pictured here, with physIQ's continuous monitoring platform to evaluate the device's efficacy in patients with heart failure. Image courtesy of Corvia Medical.

News | Heart Failure | September 12, 2019
Corvia Medical has sponsored and is actively enrolling patients in a heart failure (HF) device trial that, in addition...
 Tiny Wearable Cameras May Improve Quality of Life in Heart Failure Patients

Image courtesy of Amazon.com

News | Heart Failure | September 11, 2019
The ever-present devices that seem to track all our moves can be annoying, intrusive or worse, but for heart failure...
PARAGON-HF Misses Endpoint in Preserved Heart Failure
News | Heart Failure | September 11, 2019
The angiotensin neprilysin inhibitor sacubitril/valsartan (Entresto) missed its primary endpoint of reducing total...
Overlay Init